Funding for this research was provided by:
National Institutes of Health (5T32GM08349, 1R01EB021336, P30CA014520, 1R01CA169365, T32GM008505)
National Science Foundation (DGE-1256259)
American Cancer Society (125246-RSG-13-099-01-CCE)
Text and Data Mining valid from 2017-08-18
Received: 6 March 2017
Accepted: 25 July 2017
First Online: 18 August 2017
Compliance with ethical standards
: This work was supported, in part, by the University of Wisconsin – Madison, the National Institutes of Health (NIBIB/NCI 1R01CA169365, 1R01EB021336, P30CA014520, 5T32GM08349, T32GM008505), the National Science Foundation (DGE-1256259) and the American Cancer Society (125246-RSG-13-099-01-CCE).
: C.P. Theuer is the CEO of TRACON Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.